MiR-204 inhibits human NSCLC metastasis through suppression of NUAK1

British Journal of Cancer

Volumn 111, Issue 12, 2014, Pages 2316-2327

  Shi, L ^a   Zhang, B ^a   Sun, X ^a   Lu, S ^a   Liu, Z ^a   Liu, Y ^a   Li, H ^a   Wang, L ^a   Wang, X ^a   Zhao, C ^a  

^a WEIFANG MEDICAL UNIVERSITY   (China)

Author keywords

invasion; miR 204; mTOR; NUAK1

Indexed keywords

F ACTIN; GELATINASE A; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MICRORNA 204; NUAK1 PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; MIRN204 MICRORNA, HUMAN; NUAK1 PROTEIN, HUMAN; PROTEIN KINASE; REPRESSOR PROTEIN;

3' UNTRANSLATED REGION; ANIMAL CELL; ARTICLE; BINDING SITE; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DISTANT METASTASIS; DNA METHYLATION; DOWN REGULATION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG METASTASIS; LYMPH NODE METASTASIS; MOLECULAR PATHOLOGY; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN POLYMERIZATION; REAL TIME POLYMERASE CHAIN REACTION; SUPPRESSOR GENE; TUMOR INVASION; UPREGULATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; LUNG TUMOR; MALE; METABOLISM; METASTASIS; NUDE MOUSE; PATHOLOGY; PROGNOSIS; SURVIVAL; XENOGRAFT;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; GENE KNOCKDOWN TECHNIQUES; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; MICRORNAS; NEOPLASM METASTASIS; PROGNOSIS; PROTEIN KINASES; REPRESSOR PROTEINS; SURVIVAL ANALYSIS; TRANSFECTION;

EID: 84927571232     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.580     Document Type: Article

References (56)

1. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN (1987) A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 47(12): 3239-3245.
2. Ambros V (2008) The evolution of our thinking about microRNAs. Nat Med 14(10): 1036-1040.
3. Arber S, Barbayannis FA, Hanser H, Schneider C, Stanyon CA, Bernard O, Caroni P (1998) Regulation of actin dynamics through phosphorylation of cofilin by LIM-kinase. Nature 393(6687): 805-809.
4. Balaguer F, Link A, Lozano JJ, Cuatrecasas M, Nagasaka T, Boland CR, Goel A (2010) Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis. Cancer Res 70(16): 6609-6618.
5. Bell RE, Khaled M, Netanely D, Schubert S, Golan T, Buxbaum A, Janas MM, Postolsky B, Goldberg MS, Shamir R, Levy C (2014) Transcription factor/microRNA axis blocks melanoma invasion program by miR-211 targeting NUAK1. J Invest Dermatol 134(2): 441-451.
6. Buyukcelik A, Yalcin B, Utkan G (2004) Multidisciplinary management of lung cancer. N Engl J Med 350(19): 2008-2010.
7. Cai J, Wu J, Zhang H, Fang L, Huang Y, Yang Y, Zhu X, Li R, Li M (2013) miR-186 downregulation correlates with poor survival in lung adenocarcinoma, where it interferes with cell-cycle regulation. Cancer Res 73(2): 756-766.
8. Chang XZ, Yu J, Liu HY, Dong RH, Cao XC (2012) ARK5 is associated with the invasive and metastatic potential of human breast cancer cells. J Cancer Res Clin Oncol 138(2): 247-254.
9. Chen Z, Sangwan V, Banerjee S, Mackenzie T, Dudeja V, Li X, Wang H, Vickers SM, Saluja AK (2013) miR-204 mediated loss of Myeloid cell leukemia-1 results in pancreatic cancer cell death. Mol Cancer 12(1): 105.
10. Cheng GZ, Zhang W, Wang LH (2008) Regulation of cancer cell survival, migration, and invasion by Twist: AKT2 comes to interplay. Cancer Res 68(4): 957-960.
11. Chung TK, Lau TS, Cheung TH, Yim SF, Lo KW, Siu NS, Chan LK, Yu MY, Kwong J, Doran G, Barroilhet LM, Ng AS, Wong RR, Wang VW, Mok SC, Smith DI, Berkowitz RS, Wong YF (2012) Dysregulation of microRNA-204 mediates migration and invasion of endometrial cancer by regulating FOXC1. Int J Cancer 130(5): 1036-1045.
12. Das G, Shiras A, Shanmuganandam K, Shastry P (2011) Rictor regulates MMP-9 activity and invasion through Raf-1-MEK-ERK signaling pathway in glioma cells. Mol Carcinog 50(6): 412-423.
13. Egger G, Liang G, Aparicio A, Jones PA (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429(6990): 457-463.
14. Garzon R, Calin GA, Croce CM (2009) MicroRNAs in cancer. Annu Rev Med 60: 167-179.
15. Garzon R, Marcucci G (2012) Potential of microRNAs for cancer diagnostics, prognostication and therapy. Curr Opin Oncol 24(6): 655-659.
16. Ghosh M, Song X, Mouneimne G, Sidani M, Lawrence DS, Condeelis JS (2004) Cofilin promotes actin polymerization and defines the direction of cell motility. Science 304(5671): 743-746.
17. Gong M, Ma J, Li M, Zhou M, Hock JM, Yu X (2012) MicroRNA-204 critically regulates carcinogenesis in malignant peripheral nerve sheath tumors. Neuro Oncol 14(8): 1007-1017.
18. Imam JS, Plyler JR, Bansal H, Prajapati S, Bansal S, Rebeles J, Chen HI, Chang YF, Panneerdoss S, Zoghi B, Buddavarapu KC, Broaddus R, Hornsby P, Tomlinson G, Dome J, Vadlamudi RK, Pertsemlidis A, Chen Y, Rao MK (2012) Genomic loss of tumor suppressor miRNA-204 promotes cancer cell migration and invasion by activating AKT/mTOR/Rac1 signaling and actin reorganization. PLoS One 7(12): e52397.
19. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2): 69-90.
20. Khan N, Afaq F, Khusro FH, Mustafa Adhami V, Suh Y, Mukhtar H (2012) Dual inhibition of phosphatidylinositol 3-kinase/Akt and mammalian target of rapamycin signaling in human nonsmall cell lung cancer cells by a dietary flavonoid fisetin. Int J Cancer 130(7): 1695-1705.
21. Kozaki K, Imoto I, Mogi S, Omura K, Inazawa J (2008) Exploration of tumorsuppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 68(7): 2094-2105.
22. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, Rajewsky N (2005) Combinatorial microRNA target predictions. Nat Genet 37(5): 495-500.
23. Kusakai G, Suzuki A, Ogura T, Miyamoto S, Ochiai A, Kaminishi M, Esumi H (2004) ARK5 expression in colorectal cancer and its implications for tumor progression. Am J Pathol 164(3): 987-995.
24. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T (2001) Identification of novel genes coding for small expressed RNAs. Science 294(5543): 853-858.
25. Lam EK, Wang X, Shin VY, Zhang S, Morrison H, Sun J, Ng EK, Yu J, Jin H (2011) A microRNA contribution to aberrant Ras activation in gastric cancer. Am J Transl Res 3(2): 209-218.
26. Lee Y, Yang X, Huang Y, Fan H, Zhang Q, Wu Y, Li J, Hasina R, Cheng C, Lingen MW, Gerstein MB, Weichselbaum RR, Xing HR, Lussier YA (2010) Network modeling identifies molecular functions targeted by miR-204 to suppress head and neck tumor metastasis. PLoS Comput Biol 6(4): e1000730.
27. Li H, Yin C, Zhang B, Sun Y, Shi L, Liu N, Liang S, Lu S, Liu Y, Zhang J, Li F, Li W, Liu F, Sun L, Qi Y (2013) PTTG1 promotes migration and invasion of human non-small cell lung cancer cells and is modulated by miR-186. Carcinogenesis 34(9): 2145-2155.
28. Li J, Guan HY, Gong LY, Song LB, Zhang N, Wu J, Yuan J, Zheng YJ, Huang ZS, Li M (2008) Clinical significance of sphingosine kinase-1 expression in human astrocytomas progression and overall patient survival. Clin Cancer Res 14(21): 6996-7003.
29. Li X, Tai HH (2012) Increased expression of matrix metalloproteinases mediates thromboxane A2-induced invasion in lung cancer cells. Curr Cancer Drug Targets 12(6): 703-715.
30. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS, Johnson JM (2005) Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433(7027): 769-773.
31. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR (2005) MicroRNA expression profiles classify human cancers. Nature 435(7043): 834-838.
32. Lu S, Niu N, Guo H, Tang J, Guo W, Liu Z, Shi L, Sun T, Zhou F, Li H, Zhang J, Zhang B (2013) ARK5 promotes glioma cell invasion, and its elevated expression is correlated with poor clinical outcome. Eur J Cancer 49(3): 752-763.
33. McAuliffe PF, Meric-Bernstam F, Mills GB, Gonzalez-Angulo AM (2010) Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis. Clin Breast Cancer 10(Suppl 3): S59-S65.
34. Nishita M, Tomizawa C, Yamamoto M, Horita Y, Ohashi K, Mizuno K (2005) Spatial and temporal regulation of cofilin activity by LIM kinase and Slingshot is critical for directional cell migration. J Cell Biol 171(2): 349-359.
35. Perlikos F, Harrington KJ, Syrigos KN (2013) Key molecular mechanisms in lung cancer invasion and metastasis: a comprehensive review. Crit Rev Oncol Hematol 87(1): 1-11.
36. Pignot G, Cizeron-Clairac G, Vacher S, Susini A, Tozlu S, Vieillefond A, Zerbib M, Lidereau R, Debre B, Amsellem-Ouazana D, Bieche I (2013) microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer. Int J Cancer 132(11): 2479-2491.
37. Ren X, McHale CM, Skibola CF, Smith AH, Smith MT, Zhang L (2011) An emerging role for epigenetic dysregulation in arsenic toxicity and carcinogenesis. Environ Health Perspect 119(1): 11-19.
38. Ryan BM, Robles AI, Harris CC (2010) Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 10(6): 389-402.
39. Sacconi A, Biagioni F, Canu V, Mori F, Di Benedetto A, Lorenzon L, Ercolani C, Di Agostino S, Cambria AM, Germoni S, Grasso G, Blandino R, Panebianco V, Ziparo V, Federici O, Muti P, Strano S, Carboni F, Mottolese M, Diodoro M, Pescarmona E, Garofalo A, Blandino G (2012) miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. Cell Death Dis 3: e423.
40. Suzuki A, Kusakai G, Kishimoto A, Lu J, Ogura T, Esumi H (2003) ARK5 suppresses the cell death induced by nutrient starvation and death receptors via inhibition of caspase 8 activation, but not by chemotherapeutic agents or UV irradiation. Oncogene 22(40): 6177-6182.
41. Suzuki A, Lu J, Kusakai G, Kishimoto A, Ogura T, Esumi H (2004) ARK5 is a tumor invasion-associated factor downstream of Akt signaling. Mol Cell Biol 24(8): 3526-3535.
42. Takemoto N, Tada M, Hida Y, Asano T, Cheng S, Kuramae T, Hamada J, Miyamoto M, Kondo S, Moriuchi T (2007) Low expression of reversioninducing cysteine-rich protein with Kazal motifs (RECK) indicates a shorter survival after resection in patients with adenocarcinoma of the lung. Lung Cancer 58(3): 376-383.
43. Tan LP, Seinen E, Duns G, de Jong D, Sibon OC, Poppema S, Kroesen BJ, Kok K, van den Berg A (2009) A high throughput experimental approach to identify miRNA targets in human cells. Nucleic Acids Res 37(20): e137.
44. Turner DP, Findlay VJ, Moussa O, Semenchenko VI, Watson PM, LaRue AC, Desouki MM, Fraig M, Watson DK (2011) Mechanisms and functional consequences of PDEF protein expression loss during prostate cancer progression. Prostate 71(16): 1723-1735.
45. Ventura A, Jacks T (2009) MicroRNAs and cancer: short RNAs go a long way. Cell 136(4): 586-591.
46. Ventura AC, Jackson TL, Merajver SD (2009) On the role of cell signaling models in cancer research. Cancer Res 69(2): 400-402.
47. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103(7): 2257-2261.
48. Weng Y, Cai M, Zhu J, Geng J, Zhu K, Jin X, Ding W (2013) Matrix metalloproteinase activity in early-stage lung cancer. Onkologie 36(5): 256-259.
49. Wynter CV (2006) The dialectics of cancer: a theory of the initiation and development of cancer through errors in RNAi. Med Hypotheses 66(3): 612-635.
50. Xu Z, Liu D, Fan C, Luan L, Zhang X, Wang E (2013) DIXDC1 increases the invasion and migration ability of non-small-cell lung cancer cells via the PI3K-AKT/AP-1 pathway. Mol Carcinog 53(11): 917-925.
51. Ying Z, Li Y, Wu J, Zhu X, Yang Y, Tian H, Li W, Hu B, Cheng SY, Li M (2013) Loss of miR-204 expression enhances glioma migration and stem cell-like phenotype. Cancer Res 73(2): 990-999.
52. Yoo CB, Jones PA (2006) Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5(1): 37-50.
53. Zhang B, Gu F, She C, Guo H, Li W, Niu R, Fu L, Zhang N, Ma Y (2009a) Reduction of Akt2 inhibits migration and invasion of glioma cells. Int J Cancer 125(3): 585-595.
54. Zhang B, Ma Y, Guo H, Sun B, Niu R, Ying G, Zhang N (2009b) Akt2 is required for macrophage chemotaxis. Eur J Immunol 39(3): 894-901.
55. Zhang F, Zhang X, Li M, Chen P, Zhang B, Guo H, Cao W, Wei X, Cao X, Hao X, Zhang N (2010) mTOR complex component Rictor interacts with PKCzeta and regulates cancer cell metastasis. Cancer Res 70(22): 9360-9370.
56. Zhang L, Wang X, Chen P (2013) MiR-204 down regulates SIRT1 and reverts SIRT1-induced epithelial-mesenchymal transition, anoikis resistance and invasion in gastric cancer cells. BMC Cancer 13: 290.